Cargando…
Preliminary study highlights the potential of immune checkpoint inhibitors in sarcomatoid mesothelioma
BACKGROUND: Malignant pleural mesothelioma (MPM) is well known as an aggressive disease with poor survival. This has sparked trials of alternate immune-based therapies in MPM. While up to a quarter of MPM patients respond to immune checkpoint inhibitors (ICIs), predicting response remains challengin...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
AME Publishing Company
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7354134/ https://www.ncbi.nlm.nih.gov/pubmed/32676326 http://dx.doi.org/10.21037/tlcr-19-485 |